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Zusammenfassung
Voraussetzung für das progressive Wachstum von soli-
den Tumoren und deren Metastasen ist die Neovaskulari-
sierung. Die Regulierung dieses Prozesses erfolgt durch
Wachstumsfaktoren, zu denen unter anderem VEGF,
bFGF und die Metalloproteinasen gehören. Die Angioge-
nesehemmung stellt einen innovativen Therapieansatz
zur Behandlung von malignen Tumoren dar. Präklinische
Untersuchungen sind sehr erfolgreich verlaufen, in klini-
schen Studien konnten jedoch bislang nur in einigen Fäl-
len bedeutsame Ansprechraten gezeigt werden. Dieses
könnte auf das Vorliegen von verschiedenen angiogenen
Phänotypen beim Menschen hindeuten. Offensichtlich
sind die vielfältigen Interaktionen zwischen den angio-
gen wirksamen Zytokinen erst zum Teil bekannt. Noch
immer werden zudem neue Rezeptor-Ligandensysteme
beschrieben, die regulierend in die Neovaskularisierung
eingreifen. Der Artikel gibt eine Übersicht über die wich-
tigsten angiogen aktiven Substanzen, präklinische und
klinische Daten, verwendete Surrogatmarker sowie Zu-
kunftsaussichten.
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Summary
Neovascularization is a prerequisite for progressive
growth of solid tumors and their metastases. This
process is tightly regulated by a large number of proan-
giogenic and antiangiogenic factors such as VEGF, bFGF
and matrix-metalloproteinases. The inhibition of angio-
genesis is an innovative therapeutic approach and could
represent a powerful adjunct to traditional therapy of
malignant tumors. Preclinical trials have been very suc-
cessful but in clinical studies meaningful response rates
could only be shown in some cases. This might indicate
the existence of different angiogenic phenotypes in hu-
mans. It seems that at present only a part of the interac-
tions between the angiogenic cytokines are known. In
addition, new receptor/ligand systems which regulate
the neovascularization are being described. This article
presents an overview of the most important angiogeni-
cally active substances, preclinical and clinical data, sur-
rogate markers as well as future perspectives.
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Introduction
Malignant tumors are not primarily integrated in the existing
vessel system so that nutrients acquired through diffusion are
not substantial enough for progressive neoplasm and metasta-
sis growth above a few mm in diameter. Thus, a connection to
the body’s nutritive system is essential for growth and spread. 
Angiogenesis usually occurs primarily during the embryonic
development. In adults it is quiescent, becoming locally and
transiently activated for its involvement in the physiological
processes of the female reproductive cycle, hair-growth, and
wound healing. In malignant tumors the development and
spread of new capillaries (neovascularization) is directed and
regulated by a complex network of mechanisms which control
tumor angiogenesis via positively and negatively effective an-
giogenic factors. This implies that the physiological balance
which usually exists between oncogens (positive angiogenic
factors) and tumor suppressors (negative angiogenic factors)
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is disturbed. Alongside genetic changes during tumorgenesis
oncogens are activated and tumor suppressors are inactivated,
which leads to an overexpression of proangiogenic cytokines
and a loss of the protective effects of the tumor suppressor
genes (e.g. p53) in cancer cells. This is commonly termed the
angiogenic switch.
Once a tumor has been invaded by blood vessels, the solid
mass is supplied with oxygen and an exchange of metabolites
occurs. Neovascularization can be further stimulated by factors
being secreted by the tumor. These ‘leaky’ vessels enable the
tumor to metastasize via the vascular system to various sites.
The inhibition of angiogenesis is a promising new therapeutic
strategy for the medical treatment of malignant tumors. In
contrast to conventional therapies, antiangiogenic therapy
does not aim to directly destroy or remove the tumor, but to
prevent growth by blocking the supply of nutrients and the re-
moval of metabolites. 
As a common cell type to all solid tumors, endothelial cells
represent a preferential target for antiangiogenic cancer ther-
apy. An acquired drug resistance against antiangiogenic drugs
is not expected due to the genetic stability of endothelial cells
in contrast to the rapidly mutating, genetically unstable cancer
cells. Furthermore, no severe toxicities are expected. There-
fore, new diagnostic tools are necessary to assess biological ac-
tivity of each compound to define the optimal dose. This is in
striking contrast to treatment with cytotoxic compounds that
are used at the maximal tolerable dose (MTD). 
The block of tumor growth by antiangiogenesis requires a
chronic inhibition of vascular recruitment so that a long-term
treatment is necessary and an oral administration of drugs is
recommended.
There is a great diversity of drugs and corresponding molecu-
lar targets which can influence angiogenesis. They can be sub-
divided into several categories such as endogenous proangio-
genic factors, endogenous inhibitors, unspecific endothelial
cell inhibitors and inhibitors of communication between en-
dothelial and mesenchymal cells. The most important of these
factors as well as the surrogate markers used to assess their bi-
ological activity will be presented in the following article.
Most Relevant Proangiogenic Factors
VEGF (vascular endothelial growth factor) is known as one of
the most important regulators of angiogenesis. The biological
effects on vessels are mediated by two specific receptors,
KDR and flt-1. These receptors are mainly expressed on pro-
liferating endothelial cells. Neovascularization is stimulated
directly by an increase in proliferation and migration of the
endothelial cells, and indirectly due to hyperpermeabilization
of the vessels. The latter leads to a release of plasma proteins,
which in turn generates an adequate environment for new ves-
sel growth. VEGF is produced by tumor cells, the expression
in tumors is upregulated in comparison to that of normal tis-
sue [1]. Several VEGF antagonists have been developed
which have lead to very promising results in vitro and in ani-
mal models. It could be shown that inhibitors are able to
greatly reduce the size of tumors and the number of vessels.
The VEGF-antibody HuMV and the small molecular-weight
inhibitors of the VEGF2 (KDR) receptor tyrosine kinase,
PTK787/ZK22254 and SU 5416, belong to the most effective
substances [2–4]. The newer substances, like SU 6668 and
ZD6474, are VEGF, FGF (fibroblast growth factor) and
PDGF (platelet derived growth factor) receptor tyrosine ki-
nase inhibitors [5, 6]. Caused by their multiple inhibition prop-
erties of other proangiogenic factors it was shown that a high-
er antiangiogenic effect is the result, although the risk of side
effects might increase.
Most Relevant Antiangiogenic Factors
Angiostatin (a 38 kDa plasminogen fragment) and endostatin
(a collagen XVIII fragment) are endogenous inhibitors of an-
giogenesis, inhibiting ATP synthase and thus preventing en-
dothelial cell proliferation. For quite a long time specific re-
ceptors as well as the signal transduction pathway for these
factors could not be identified. 
Recently however, the inhibitory effect of endostatin on MMP
(matrix metalloproteinase) activation from proMMPs as well
as integrins has been described as a possible mechanism. Ex-
cellent results with complete tumor regression could be shown
in animal models, where, remarkably, even after several cycles
the animals did not develop resistance to the therapy and no
new tumor growth occurred after therapy termination [7, 8]. 
Thrombospondin-1 (TSP-1) is expressed by blood platelets as
well as many other cells. Alongside its various defined
functions, it is also known to have an antiangiogenic effect.
The so-called type-one repeats and, to a lesser extent, the pro-
collagen-homology-region (both being TSP subunits) are re-
sponsible for the antiangiogenic effect of TSP-1 and are medi-
ated by the CD36 receptors on the microvascular endothelial
cells. Both TSP and the type-one-repeat fusion proteins have
shown strong antiangiogenic activity in vitro and in animal
models [9].
Cell-Cell Interaction in Angiogenesis
The matrix-metalloproteinases (MMPs) are a group of more
than 20 enzymes. They have the ability to degrade compo-
nents of the extracellular matrix, which is a prerequisite for
the proliferation of tumor cells and neovascularization. A
physiological balance exists between MMPs and TIMPs (tis-
sue inhibitors of MMPs). In tumor stroma cells, but also in
tumor cells, overexpression of various MMPs, especially
MMP-2 and -9, occurs in comparison to normal tissue. In pre-
clinical studies, MMP inhibitors have been shown to inhibit
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proliferation in tumor cell lines and EC (endothelial cell) lines
as well as in animal models [10, 11]. A distinction was made
between unspecific substances which affect several MMPs and
those which especially inhibit MMP-2, -3 and -9. Batimastat,
marimastat, AG 3340 (prionomastat) and CGS 27023A are all
agents with pleiotropic effect. Neovastat (AE 941), a shark
cartilage extract, is also an unspecific MMP-inhibitor, which
contains TIMP-like substances. These substances are responsi-
ble for part of the effects. A VEGF inhibiting effect has also
been described as a further mechanism. BAY 12-9566 and
BMS-275291 are examples of more specific second-generation
MMP inhibitors which act more selectively against MMP-2, -3
and -9 [12]. COL-3 (Metastat) is a tetracycline derivative
with a relatively high specificity for MMP-2 and -9.
The integrins are a group of more than 22 cell-surface glyco-
proteins, which are composed of alpha and beta chains. These
mediate specific molecular interactions between vascular cells
and the extracellular matrix and are capable of recognizing
the so-called RGD sequence present in their ligands, the ex-
tracellular matrix proteins. Integrins are able to distinguish be-
tween different proteins in the extracellular matrix due to the
specificity of the RGD sequence. As angiogenesis is depen-
dent on specific molecular interactions between vascular cells
and the extracellular matrix, it has been concluded that inte-
grins are of functional importance in this process. Although
minimal integrin expression takes place on normal blood ves-
sels, a significantly higher expression can be found on tumor
blood vessels. The αvβ3 and αvβ5 integrins play a critical role
in angiogenesis. FGF- and VEGF-induced cell proliferation
could be blocked in vitro. Several inhibitors are known: Vi-
taxin (LM 609), a monoclonal anti-αvβ5 antibody, Sch
221153, a small-molecular-weight peptide which antagonizes
αvβ3 and αvβ5 and EMD 121974, an αvβ3 inhibitor [13–15].
All of these substances have shown an antiangiogenic effect in
vitro and in animal models. 
Clinical Studies
After several antiangiogenic substances were extremely suc-
cessful in vitro and in animal models, many drugs are current-
ly being evaluated in classical phase I–III clinical studies
(table 1). In addition, different techniques are used as surro-
gate markers to assess biological activity that might occur
below the MTD and might define the optimal dose. 
Inhibition of Proangiogenic Cytokines
PTK787/ZK22254, a small-molecular-weight antagonist of the
VEGF receptor KDR, is one of the first antiangiogenic sub-
stances to be tested in clinical studies in Germany. This com-
pound is studied in patients with solid tumors and glioblas-
toma in different phase I studies. Stable disease (SD) up to 15
months could be recorded in approximately half of the pa-
tients, mainly with colorectal and breast cancer. Best respons-
es observed were minor responses (MR). Dose-limiting toxic-
ity did not occur up to a dose of 2,000 mg/d. The most com-
mon side effects like ataxia and worsening of preexisting hy-
pertension were reversible. Having investigated the detection
of serum levels of soluble proangiogenic factors, of tumor
blood flow by color Doppler imaging and of tumor permeabil-
ity by dynamic contrast-enhanced magnetic resonance imag-
ing (dceMRI) as surrogate markers to detect biological activi-
ty, the optimal dose of PTK787/ZK222584 was defined at
1,200 mg/d. The studies are ongoing and a phase II/III study is
planed after completion of phase I [16].
SU 5416, another VEGF receptor antagonist, is presently
being tested on patients with advanced tumors in several
phase I–III studies. A phase I study had already shown clinical
activity in NSCLC (non-small cell lung cancer). From 8 pa-
tients in a phase II study on patients with malignant
melanoma, 1 showed SD and 1 PR (partial remission). Toxici-
ty consisted of diarrhea, allergic reactions, and fatigue. The
optimal dosage was found to be 145 mg/m2 twice a week [17].
One disadvantage of this substance is the i.v. formulation.
Therefore, a further phase I study is being carried out in order
to test oral bioavailability. Preliminary data are promising. So
far, the use of positron emission tomography (PET) and in-
travital microscopy did not result in any detection of biologi-
cal activity. Several studies in which SU 5416 is applied in
combination with various chemotherapies or immunothera-
pies are not yet completed. Preliminary data do not show in-
creased toxicity in comparison with chemotherapy alone.
Pfizer is developing CP-547.632, a novel isothiazole selective
for KDR inhibition. CP-547.632 is orally bioavailable, well-
tolerated, and is currently in phase I trials in cancer patients.
Preliminary human pharmacokinetics data in advanced can-
cer patients were recently disclosed: 24 patients receiving oral
administration of CP-547.632 at 35 mg for 14 days to 160 mg
per day continuously for a median of 2 courses (range 1–7)
[18]. Half-life was estimated to be 29 h. No dose-limiting toxi-
city or treatment discontinuations were observed in either of
the dose cohorts except for a transient non-maculopapular
rash and dry mouth observed in 2 of 24 patients. Disease sta-
bilization was observed in 6 of 22 evaluable patients. 
Sporadic incidences of SD with low toxicity could be recorded
within a continuing phase I study with orally applied ZD 6474,
a VEGF and EGF receptor antagonist [19]. The most relevant
toxicities were described as skin rash, QT-prolongation and
diarrhea, all possibly related to the EGF-receptor activity. 
The newest substance in this group is SU 6668, a multiple
tyrosine kinase receptor inhibitor (KDR, PDGF-R, FGF-R1,
C-KIT), which can be applied orally. The interim report of a
phase I study informed about several patients with SD up to 
6 months and one MR. Mild to moderate toxicity occurred in
form of fatigue, pleural pain and thrombopenia. Optimal
doses described are 1600 mg/m2/d, and were chosen from
pharmacokinetics. The use of proteomic techniques did not
result in the detection of biological activity [5].
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[29]. An additive effect in combination with paclitaxel and
carboplatin in comparison to chemotherapy alone in patients
with NSCLC could not be observed [30, 31]. 
Marked muscular-skeletal side effects occurred with the
named metalloproteinase inhibitors, especially a dose-limiting
inflammatory polyarthritis. The reason for these side effects is
obviously high MMP expression in joints. The recommended
doses for marimastat and prionomastat are 10 and 25 mg/d.
There are as yet no results for CGS 27023 A, also unspecific.
Relevant phase I studies are ongoing.
It is assumed that the results of the current studies with the in-
hibitors BMS 275294 and COL-3, specific against MMP-2 and
-9, will be very promising. MMP-2 and -9 are upregulated in
tumors and obviously have an important function in tumor de-
velopment. Fewer musculoskeletal side effects are expected
due to their relatively specific effect [32]. COL-3 is being test-
ed in phase I studies on patients with advanced solid tumors.
Preliminary results in patients with non-epithelial malignomas
show that SD could be achieved. Phototoxicity and fatigue
were dose-limiting factors [33]. No data are available for the
response rates with BMS 275291 at present. As expected, no
dose-limiting polyarthritis could be recorded in one phase I
study. Mild side effects included grade I–II myalgia/athralgia.
The recommended dose for further studies is defined as 1,200
mg/d for BMS 275291 and 70 mg/m2/d for Col-3.
Neovastat is exceptional as an unspecific MMP inhibitor and is
at present being tested for the treatment of kidney cancer in
phase II studies, as well as multiple myeloma and lung carci-
nomas in phase III studies. Preliminary data could show a sig-
nificant increase in median survival describing taste alter-
ations as side effects [34].
The reason for the generally disappointing results for MMP
inhibition until now could be the choice of tumor type for clin-
ical studies. In preclinical studies, MMP inhibitors proved to
be most effective with renal cell carcinoma and malignant
melanoma. No declaration of clinical efficacy has yet been
made for these tumor types.
Integrin Antagonists
Integrin antagonists are currently being tested in several
phase I–II studies. One phase I study with Vitaxin has been
completed. Notable response rates were not recorded, howev-
er SD could be shown in 3 patients. Circulatory antibodies
could be continually measured without toxicity using an i.v.
application of the antibody with doses of 2.5–3.5 mg/kg every
3 weeks [35]. EMD 121974 is currently being tested on pa-
tients with anaplastic glioma (phase I/II) and Kaposi’s sarcoma
(phase I). Early presentations are describing stable diseases
under this compound [36]. Another case of SD could only be
described in one patient in a phase I study involving patients
with various solid tumors. The dose levels ranged up to 800
mg/m2 twice a week. Changes of soluble TIE-2 (angiopoetin
receptor 2) could be observed, suggesting its role as surrogate
for EMD 121974.
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Cephalon is studying CEP-7055, an orally active selective pan-
VEGF receptor kinase inhibitor in Phase I clinical studies
[20]. CEP-7055 is the N,N-dimethyl glycine ester pro-drug of
CEP-5214, a water-soluble, orally active substituted fused
pyrrolocarbazole that inhibits KDR, Flt-1 and Flt-4 with IC50
values of 18, 12 and 17 nM, respectively. 
Anti-VEGF antibody therapy is currently studied in clinical
phase I and III studies. For Bevamizumab (Avastin), an anti-
VEGF antibody used in doses of 5–15 mg/kg every other
week, sporadic cases of SD are described. Deep-vein throm-
bosis, hypertension, proteinuria, bleedings, cramps and dysp-
noe were described as main drug-related side effects [21]. Op-
timal dose for anti-VEGF-receptor antibody therapy, as stud-
ied in phase I trials with IMC-1C11, is not yet defined, al-
though changes in dceMRI are already described in initial
doses of 0.2–4 mg/kg [22].
Therapeutic Use of Endogenous Antiangiogenic Factors
Clinical studies have been delayed due to the amount of
recombinant endostatin and angiostatin required to induce
anti-tumor effects in humans. Meanwhile, phase I studies on
patients with various solid tumors are being carried out. First
data on endostatin, presented at ASCO 2001, showed that the
equivalent doses used in animal models (300 mg/m2) had no
effect on the tumors. SD could be shown sporadically; grade
III and IV toxicity did not occur [23, 24]. At ASCO 2002, first
minor responses and disease stabilization could be reported
for angiostatin and endostatin [25, 26]. MTD of endostatin is
detected at 240 mg/m2 for daily i.v. and 60 mg/m2 for continu-
os infusion. Side effects observed (erythema with angiostatin
and rash with endostatin) were moderate. Surrogate markers
like VEGF and bFGF concentrations in urine as well as circu-
lating endothelial cells, changed under therapy with endo-
statin indicating biological activity at low doses. In contrast,
no changes in dceMRI are described under treatment with
angiostatin.
Inhibition of Cell-Cell Interaction in Tumorangiogenesis
In the past few years a number of phase I–III studies have
been carried out using MMP inhibitors. The results of the
broad spectrum MMP inhibitors batimastat and marimastat
were mainly disappointing. No antitumoral effect could be
achieved with a single substance. A longer survival without
progression and total survival after marimastat application
was recorded in one study on patients with advanced stomach
carcinoma [27]. A 75% response rate was achieved in combi-
nation therapies with doxorubicin and docetaxel in patients
with advanced breast carcinoma [28]. In other studies, using
the same combination in breast cancer patients, response rates
of 57–77% could be observed. Marimastat is currently being
used in studies on metastasized tumors (e.g. SCLC) to prevent
disease progression after completion of chemotherapy.
In a phase II study on prionomastat with patients with ad-
vanced breast cancer, SD could be achieved in 5 of 44 patients
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Compounds with Unknown Antiangiogenic Mechanism
Thalidomide, a glutamic acid derivative, is well-known due to
its teratogenetic effects, which have been attributed to its an-
tiangiogenic mechanisms. It involves the modulation of vari-
ous proangiogenic cytokines, e.g. of VEGF and bFGF [37, 38].
Thalidomide is studied in a variety of solid tumors. In certain
phase I–III studies SD up to CR could be described at optimal
doses of 300 mg/m2. Sedation, thrombosis, and neurologic tox-
icity represent the main toxicities, especially in higher doses
(400–1,200 mg/d) used in earlier trials. In the treatment of re-
fractory or relapsed multiple myeloma, impressive response
rates of 30% could be achieved. In a phase II trial in patients
with recurrent high-grade gliomas (final daily dose 1,200 mg)
notable response rates could not be observed, but SD was
recorded in 33% [39, 40].
IM 862 is an L-glutamyl-L-tryptophan dipeptide which in-
hibits angiogenesis by immunomodulation. It activates killer
cells and has a regulating function on several cytokines, in-
cluding VEGF. The antiangiogenic effects could be shown in
vitro and in animal models [41]. A phase I study on the treat-
ment of patients with AIDS-related Kaposi’s sarcoma with IM
862 resulted in a 36% response (CR, PR) and SD in 48%.
Negligible side effects were occasionally reported under the
applied dose of 5 mg/d. In one phase II study treating patients
with advanced ovarian cancer, a definite response could be
recorded in a single patient and SD in several others. IM 862
was applied as intranasal drops and well-tolerated at all
dosage levels. The maximum dose was 120 mg/d. Grade III
toxicity which could be attributed to IM 862 included nausea,
vomiting, and cephalalgia. The MTD is not reached [42]. Fur-
ther studies are still being carried out, also involving patients
with metastatic colorectal carcinomas. 
TNP-470, one of the first substances to be recognized to have
an antiangiogenic effect, is an analogue of the antibiotic fu-
magillin. An inhibition of bFGF-induced angiogenesis has
been shown in vitro and in vivo. An inhibition of the growth of
HUVECs (human umbilical vein endothelial cells) is possible
even with low concentrations of TNP-470. The administration
of TNP-470 to mice that had received a subcutaneous injec-
tion of pancreas tumor cells resulted in a reduction in tumor
size and the severity of metastases in comparison to untreated
animals [44]. One phase I study with TNP-470 in patients with
advanced prostate carcinoma could not show antitumoral effi-
cacy but a stimulation of PSA values in several cases [43]. In
another phase I study with patients with cervix carcinoma one
patient was recorded with CR, which continued for 8 months
after the end of the therapy [45]. A synergetic effect could be
observed in combination with carboplatin and paclitaxel, final
data on the response rates are not yet available. The main side
effects to be observed were neuropsychiatric symptoms, for
example ataxia, asthenia, and agitation. The MTD is 71
mg/m2.
Squalamine, an aminosterol, is an extract of dogfish shark
liver. After intracellular uptake it has a direct effect on acti-
vated endothelial cells. It inhibits the sodium hydrogen ex-
changer, blocking mitogen-induced proliferation and migra-
tion of endothelial cells. The exact antiangiogenic mechanism,
however, is unknown [46]. Only preliminary results of one
phase II study are available at present. The study involved pa-
tients with chemosensitive NSCLC. Squalamine was applied
in combination with carboplatin and paclitaxel. Of 18 patients
27% showed PR. Unfortunately, the study lacks a monothera-
py arm. Data from other studies show response rates of
15–28% in combined therapy with paclitaxel and carboplatin.
The optimum dosage of squalamine has been defined as 300
mg/m2/d. Side effects were neutropenia hyponatremia, raised
transaminase levels and anemia [47].
The antiangiogenic and antimetastatic effects of carboxyami-
do-triazol (CAI), a synthetic compound, are attributed to the
inhibition of calcium channels, which initiates several signal
transduction processes. The influence on angiogenesis is
caused by inhibition of VEGF and MMPs. An inhibition of
EC proliferation has been shown in vitro [48]. Results of a
phase I study with CAI are now available. 1 MR and SD in
47% of the patients were recorded. Toxicity included ataxia,
confusion and gastrointestinal side-effects. The maximum tol-
erable dose was 350 mg/m2/d. In another phase I study, CAI
was tested in combination with paclitaxel. No additional toxic-
ity could be observed [49, 50]. CAI is at present being tested
in phase II studies.
Old Drugs – New Indication
There is an increasing trend to proof compounds developed
for other indications for their antitumoral or antiangiogenic
potency [51]. Some main examples for this kind of develop-
ment are coming from angiogenesis or proapoptotic research. 
Metronomic therapy describes the use of low dose continuos
chemotherapy to treat proliferating endothelial cells. Differ-
ent cytotoxic compounds are under clinical development like
cyclophosphamide, methotrexate, and capecitabine [52]. A
German trial combines metronomic therapy (capecitabine 2 ×
1 g/m2/d p.o.) with an anti-inflammatory compound (celecoxib
1 × 25 mg/d p.o.) that is also known to be antiangiogenic and
an antidiabetic compound (actos 1 × 45 mg/d p.o.) that is also
known to be proapoptotic [53]. The profile with low side ef-
fects and responses in heavily pretreated patients supports the
ongoing investigation in known compounds with other indica-
tions.
Discussion
The results of the preclinical studies with antiangiogenic
agents had been very promising, often showing partly or com-
plete tumor regression without any drug resistance. However,
these results could not be confirmed in clinical trials. Objec-
tive tumor responses were achieved only in some cases. Espe-
cially the minimal antitumoral effects of endostatin/angio-
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statin in doses equivalent to those used in animal models has
been disappointing. VEGF receptor tyrosine kinase inhibitors
like PTK787/ZK22254 or thalidomide might actually be the
most promising substances for some tumor entities.
The differing response rates to an angiogenic drug among pa-
tients might be explained by their different angiogenic pheno-
types. The regulation of angiogenesis in humans is obviously
much more complex than previously thought. It must be pre-
sumed that neovascularization is controlled by the combined
effects of several factors with different mechanisms. New re-
ceptor/ligand systems are increasingly being described and
could be further important regulators of angiogenesis. 
It should be mentioned that the proper end-points of studies
on antiangiogenic compounds may have to differ from those
of standard chemotherapy agents. The success of conventional
chemotherapies is measured by objective response rates. Im-
proved survival or duration of stable disease may be more ap-
propriate end-points for antiangiogenic substances. From cur-
rent trials, surrogate markers like dceMRI and soluble angio-
genesis markers turn out to be most predictive for biological
activity, defining optimal doses below the MTD.
The combination of angiogenesis inhibitors with cytotoxic
chemotherapy may play an important role in the future. The
reasoning for this combination is the assumption that the vari-
ous mechanisms of action and various targets could lead to
additive antitumoral effects. Fewer side effects are to be ex-
pected than in a classic polychemotherapy. At present it is not
clear whether a combination of an angiogenesis inhibitor with
chemotherapy will yield an advantage. 
The ability to avoid acquired drug resistance is regarded to be
one of the advantages of antiangiogenic drugs over other
forms of anticancer therapy because of the nature of their cel-
lular target: genetically stable endothelial cells rather than
rapidly mutating, genetically unstable cancer cells. Recently
there is accumulating preclinical and clinical evidence that a
number of antiangiogenic drugs or strategies can lose their ac-
tivity over time. This could be caused by several possible
mechanisms, e.g. an overexpression of other proangiogenic
factors that may antagonize the function of the antiangiogenic
agents if only one such factor is the target of an antiangiogenic
therapy. For this reason the combined application of angio-
genesis inhibitors might be a promising strategy. Inhibition of
various receptor/ligand systems could be effective due to the
different mechanisms of action within the angiogenesis
process. Preliminary in-vitro data describe an increased effect
when two angiogenesis inhibitors are applied in combination
[51]. In addition, application of antiangiogenic drugs in an ad-
juvant setting might be another option. Results from clinical
studies are not yet available.
The inhibition of angiogenesis still presents an attractive pos-
sibility for treating cancer but further preclinical and clinical
studies are necessary in order to define an effective applica-
tion for this form of therapy.
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